These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29240986)

  • 21. Workplace exposure to engineered nanomaterials: the Italian path for the definition of occupational health and safety policies.
    Mirabile M; Boccuni F; Gagliardi D; Rondinone BM; Iavicoli S
    Health Policy; 2014 Jul; 117(1):128-34. PubMed ID: 24582490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of Safe-by-Design for Nanomaterial Development and Safe Innovation: Why We Need a Comprehensive Approach.
    Kraegeloh A; Suarez-Merino B; Sluijters T; Micheletti C
    Nanomaterials (Basel); 2018 Apr; 8(4):. PubMed ID: 29661997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modernizing innovation governance to meet policy ambitions through trusted environments.
    Soeteman-Hernández LG; Sutcliffe HR; Sluijters T; van Geuns J; Noorlander CW; Sips AJAM
    NanoImpact; 2021 Jan; 21():100301. PubMed ID: 35559788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Assessment and Risk Governance of Liquefied Natural Gas Development in Gladstone, Australia.
    van der Vegt RG
    Risk Anal; 2018 Sep; 38(9):1830-1846. PubMed ID: 29481704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating legal liabilities in nanomanufacturing risk management.
    Mohan M; Trump BD; Bates ME; Monica JC; Linkov I
    Environ Sci Technol; 2012 Aug; 46(15):7955-62. PubMed ID: 22717005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries.
    Amenta V; Aschberger K; Arena M; Bouwmeester H; Botelho Moniz F; Brandhoff P; Gottardo S; Marvin HJ; Mech A; Quiros Pesudo L; Rauscher H; Schoonjans R; Vettori MV; Weigel S; Peters RJ
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):463-76. PubMed ID: 26169479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expert views on regulatory preparedness for managing the risks of nanotechnologies.
    Beaudrie CE; Satterfield T; Kandlikar M; Harthorn BH
    PLoS One; 2013; 8(11):e80250. PubMed ID: 24244662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Necessity and approach to integrated nanomaterial legislation and governance.
    Wang J; Gerlach JD; Savage N; Cobb GP
    Sci Total Environ; 2013 Jan; 442():56-62. PubMed ID: 23178764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Problem formulation and option assessment (PFOA) linking governance and environmental risk assessment for technologies: a methodology for problem analysis of nanotechnologies and genetically engineered organisms.
    Nelson KC; Andow DA; Banker MJ
    J Law Med Ethics; 2009; 37(4):732-48. PubMed ID: 20122113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Legal aspects of the risks raised by nanotechnologies in the field of medicine.
    Poirot-Mazères I
    J Int Bioethique; 2011; 22(1):99-118, 212. PubMed ID: 21850972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward advancing nano-object count metrology: a best practice framework.
    Brown SC; Boyko V; Meyers G; Voetz M; Wohlleben W
    Environ Health Perspect; 2013; 121(11-12):1282-91. PubMed ID: 24076973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demand for command: responding to technological risks and scientific uncertainties.
    Stokes E
    Med Law Rev; 2013; 21(1):11-38. PubMed ID: 23329016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Creating Inquiry Between Technology Developers and Civil Society Actors: Learning from Experiences Around Nanotechnology.
    Krabbenborg L
    Sci Eng Ethics; 2016 Jun; 22(3):907-22. PubMed ID: 26040841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanotechnology: the next big thing, or much ado about nothing?
    Maynard AD
    Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards adaptive and integrated management paradigms to meet the challenges of water governance.
    Halbe J; Pahl-Wostl C; Sendzimir J; Adamowski J
    Water Sci Technol; 2013; 67(11):2651-60. PubMed ID: 23752402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Governance of environmental risk: new approaches to managing stakeholder involvement.
    Benn S; Dunphy D; Martin A
    J Environ Manage; 2009 Apr; 90(4):1567-75. PubMed ID: 18768249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (Re)imagining purpose: A framework for sustainable nanotechnology innovation.
    Jeffcoat P; Di Lernia C; Hardy C; New EJ; Chrzanowski W
    NanoImpact; 2024 Jul; 35():100511. PubMed ID: 38750963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.